MAXCYTE, INC. (MXCT): Results of Operations and Financial Condition
MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mxct-20260812xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Reports Second Quarter 2026 Financial Results · Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue · Reitera
How this was made
The 30-second read
Why it matters
Q2 results show total revenue down 15% YoY and core revenue down 21% YoY, while SPL program-related revenue rose to $0.8M. The company reiterated full-year revenue guidance of $30M to $32M and expects year-end cash of at least $130.5M (excluding further buyback deployment). The newly signed multi-platform license with Genentech is positioned as unlocking new opportunities and supporting long-term value via SPL royalties and clinical program advancement.
Market read
Traders can update models using the explicit Q2 financials and the reiterated full-year revenue and cash guidance, and reassess the revenue mix impact of SPL growth versus core weakness.
What to watch
Non-GAAP gross margin excludes SPL-related revenue and inventory reserves; traders may want to track whether SPL program-related revenue scales enough to stabilize consolidated margins and cash burn.
Background
This is an SEC Form 8-K (Item 2.02) with MaxCyte’s Q2 2026 results, full-year 2026 guidance, and related disclosures including a share repurchase update and a newly announced Genentech technology license partnership.
Ticker impact
MaxCyte reported Q2 2026 revenue of $7.3M, reiterated 2026 guidance, and disclosed a $5.5M buyback plus a Genentech multi-platform license deal.
Near-term bias upward on guidance confidence and the Genentech partnership narrative, with volatility risk from the reported core revenue decline and gross margin compression.
The article provides concrete financial figures (revenue, gross margin, net loss), explicit full-year revenue ranges, and a newly signed enterprise license partnership with Genentech, all of which are actionable for positioning. However, it does not provide deal economics (upfront/milestones/royalty rates), limiting precision on magnitude.
Market effects
Reinforces demand for cell-engineering enabling platforms and multi-platform licensing models, potentially supporting sentiment toward adjacent cell therapy tooling names.
Limited direct regional read-through; primarily US-listed biotech tooling sentiment.
Genentech partnership signals continued global large-pharma investment in enabling technologies, but deal size details are not provided here.
Counterpoint
The headline partnership may not offset the ongoing core revenue decline and gross margin deterioration, so the market could focus on whether SPL growth can sustainably replace core weakness.
Key entities
- issuerMaxCyte, Inc.
Cell-engineering enabling platform company reporting Q2 2026 results, reiterating 2026 guidance, and announcing a Genentech multi-platform technology license partnership.
- partnerGenentech
Large pharma partner named in a newly signed enterprise-level multi-platform technology license partnership with MaxCyte.
